NCT06097260Phase 2Terminated

Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

Study sponsor: Pliant Therapeutics, Inc. · PLRX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-04-04Actual
Enrollment · participants320Actual
Source updated2026-08-05Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: To characterize the effect of bexotegrast versus placebo on the change in forced vital capacity (FVC) in participants with idiopathic pulmonary fibrosis (IPF). After: Measure: Change From Baseline in Forced Vital Capacity at Week 52.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview